All In MedTech

Device Trial Radar · NCT06521463

SIMPLAAFY Clinical Trial

WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device With Alternative Post-Implant Monotherapy

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 1,857 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,857

Actual

Start

Oct 1, 2024

Primary completion

Jul 7, 2026

Study completion Jan 2027

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Jul 26, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.

Conditions

  • Atrial Fibrillation
  • Stroke
  • Bleeding

Interventions

  • WATCHMAN FLX Pro LAAC DeviceDevice

    WATCHMAN FLX Pro LAAC Device Implantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduced dose NOAC Arm Primary Endpoint: Composite rate of all death, all stroke, systemic embolism, and ISTH major bleeding at 6-months after randomization in the reduced dose NOAC arm tested for non-inferiority compared to the DAPT armTime frame: 6 months after randomization
  2. Aspirin Arm Primary Endpoint: Composite rate of all death, all stroke, systemic embolism, and ISTH major bleeding at 6-months after randomization in the Aspirin arm tested for non-inferiority compared to the DAPT arm.Time frame: 6 months after randomization

Locations

86 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama

  • Grandview Medical Center

    Birmingham, Alabama

  • Phoenix Cardiovascular Research Group

    Phoenix, Arizona

83 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.